Search
Huadong Medicine Announces Clinical Trial Approval for Subsidiary's HDM2012 Injection
2025-07-18 /
Read about 0 minute
Author：小编
Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd., a fully-owned subsidiary of Huadong Medicine, has secured approval from the National Medical Products Administration (NMPA) to initiate clinical trials for its proprietary HDM2012 Injection, a cutting-edge Class 1 biological therapeutic aimed at treating advanced solid tumors. This innovative drug stands out for its exceptional druggability, safety profile, and efficacy.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
